Composition containing xanthophylls/lutein ester and application thereof

A technology of lutein esters and lutein, applied in the field of lutein/lutein ester preparations, can solve the problem of reducing the bioavailability of lutein/lutein esters and the stability of lutein/lutein esters Sexual damage and other problems, achieve significant health care and therapeutic effects, increase eye blood flow, nutrition and health care taste effect

Active Publication Date: 2016-12-21
SINO NUTRACEUTICAL CO LTD
View PDF3 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Strong acids have a strong destructive effect on the stability of lutein/lutein esters. These products quickly enter the gastrointestinal tract after oral cons

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition containing xanthophylls/lutein ester and application thereof
  • Composition containing xanthophylls/lutein ester and application thereof
  • Composition containing xanthophylls/lutein ester and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Recipe: (weight)

[0029]

[0030]

[0031] Preparation:

[0032] The components are mixed and then prepared into orally disintegrating tablets by methods known in the art. Clinical Observation:

[0033] (1) Clinical data

[0034] A clinical trial was carried out on 220 outpatients. The clinical manifestations of these patients were dim eyesight, eye pain, weak dark adaptation, blurred vision, photophobia, dry eyes, and blinking. They were non-hospitalized and voluntarily participated in the experiment; 110 cases in the treatment group ( Male: female = 1:1), and 110 cases in the control group (male: female = 1:1).

[0035] (2) Treatment method

[0036] The control group used Zhenshiming Eye Drops, once a day, and 15 days was a course of treatment; the treatment group took the compound of the present invention orally, 550 mg / tablet, 4 tablets per day;

[0037] (3) The clinical trial results are as follows:

[0038]

[0039] There is a significant differenc...

Embodiment 2

[0041]

[0042] Clinical Observation:

[0043] (1) Clinical data

[0044] A clinical trial was carried out on 180 outpatients. The clinical manifestations of these patients were dim eyesight, eye pain, weak dark adaptation, blurred vision, photophobia, dry eyes, and blinking. They were non-hospitalized and voluntarily participated in the experiment; 100 cases in the treatment group ( Male: female = 1:1), and 80 cases in the control group (male: female = 1:1).

[0045] (2) Treatment method

[0046] The control group uses eye drops, once a day, and 15 days is a course of treatment; the treatment group takes orally the compound of the present invention, 550 mg / tablet, 4 tablets per day;

[0047] (3) The clinical trial results are as follows:

[0048]

[0049]

[0050] There are significant differences between the treatment group and the matched group, and it is concluded that the clinical application of the present invention has a significant curative effect.

[0051...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a composition containing xanthophylls/lutein ester and application thereof. The composition containing xanthophylls/lutein ester contains xanthophylls/lutein ester and beta-carotene and a pharmaceutical acceptable carrier, wherein weight ratio of xanthophylls/lutein ester to beta-carotene is 1: 0.1-100. By coordinated use of xanthophylls/lutein ester and beta-carotene and with assistance of natural healthy ingredients, the dosage form of an orally disintegrating tablet is prepared. The orally disintegrating tablet is absorbed through oral cavity, has fast effectiveness, has small first-pass effect, reduces damage of gastric acid to xanthophylls/lutein ester, has high bioavailability, and has characteristics of nutritional and health-care effects, good mouthfeel and fast absorption. By the use of the product, visual power can be obviously enhanced, ocular blood flow is increased, and eye muscle fatigue is improved. Therefore, morbidity of cataract, senile retina macular degeneration and juvenile myopia is reduced.

Description

technical field [0001] The present invention relates to lutein / lutein ester preparations. Background technique [0002] In recent years, people's study, work and entertainment have become more and more dependent on computers, TVs, mobile phones and other video display terminal equipment. They often use their eyes excessively and do not pay attention to eye maintenance, which leads to vision loss and even induces various eye diseases. Great physical and mental pain. [0003] Lutein esters are natural antioxidants present in plant cells, which are metabolized into lutein in the human body. Lutein is considered to be the "vitamin of the eyes", which has a unique effect on preventing the incidence of cataracts, age-related macular degeneration and the occurrence of myopia in teenagers. Lutein also has anti-cancer, prevents the occurrence of cardiovascular diseases, enhances Body immunity and other health effects. [0004] At present, there are various health products, efferve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/047A61K31/23A61K31/015A61P27/02A61P27/10A61P27/12
CPCA61K31/015A61K31/047A61K31/23A61K2300/00A23L33/105A23V2002/00A61K9/0056A61K31/07A61K47/02A61K47/12A61K47/26A61K47/40A61P27/02A61P27/10A61P27/12C07C403/24A23V2250/211A61K9/20
Inventor 顾茂健苏健梅
Owner SINO NUTRACEUTICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap